Sun Pharma Secures Global Rights to $3.7 Billion Cholesterol Drug Market
Sun Pharmaceutical Industries has signed a global licensing deal with US-based LIB Therapeutics for Lerodalcibep, a once-monthly cholesterol-lowering drug. The agreement grants Sun Pharma exclusive rights to commercialize and manufacture the drug outside the US and China, tapping into a $3.7 billion market for PCSK9 inhibitors. The drug was recently approved in the EU for adults with high cholesterol and mixed dyslipidaemia.
Business Standard·3h ago


